SoVarGen
Company

Last deal

$29.46M
Local Amount - KRW 35B

Amount

Series B

Stage

10.09.2020

Date

2

all rounds

$29.46M

Total amount

date founded

Financing round

General

About Company
SoVarGen develops therapeutics and diagnoses for incurable brain disorders caused by somatic mutation.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2018

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

SoVarGen focuses on providing effective treatments for patients with neurological diseases by developing diagnostics and therapeutics specifically designed to diagnose and treat intractable central nervous system (CNS) diseases caused by low-level somatic mutation. Their innovative solutions aim to help patients receive timely and targeted treatments for incurable brain disorders.
Similar Companies
1000
Attralus

Attralus

Attralus creates transformative medicines to improve patients' lives, focusing on systemic amyloidosis.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

San Francisco, CA, USA

total rounds

3

total raised

$197M
Biohope

Biohope

Biohope develops diagnostic and therapeutic solutions for organ transplantation.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Madrid, Spain

total rounds

3

total raised

$394.41K
Precision Biologics

Precision Biologics

Precision Biologics develops targeted cancer drugs and diagnostics for early detection.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Dallas, TX, USA

total rounds

4

total raised

$59.4M
NeuroDetect

NeuroDetect

NeuroDetect is a biotech company that develops FDA-compliant software for precision-guided therapies in epilepsy.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Los Angeles, CA, USA

total rounds

1

Financials

Funding Rounds
2
2

Number of Funding Rounds

$29.46M

Money Raised

Their latest funding was raised on 10.09.2020. Their latest investor Medivate Partners. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
10.09.2020
4
$29.46M
Local Amount - KRW 35B
01.01.2020
1
Co-Investors
Investors
5
0

Number of lead investors

5

Number of investors

Investor 
Lead 
Round 
Partners 
Medivate Partners

Medivate Partners

Medivate Partners is a Seoul-based private equity firm investing in growth-stage companies in life sciences, healthcare, and biotech.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Venture Capital, Financial Services

Location

Seoul, South Korea

count Of Investments

9

count Of Exists

3
K and Investment Partners

K and Investment Partners

IBKC-K& Secondary No1 is a secondaries fund investing in bio-medical and next-generation energy IT convergence sectors.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Consulting

Location

Seoul, South Korea

count Of Investments

15
NH Investment & Securities

NH Investment & Securities

NH Investment & Securities is a South Korean company providing wealth management, investment banking, trading, and equity sales.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Wealth Management, Finance

Location

Seoul, South Korea

count Of Investments

57

count Of Exists

1

Activity

Recent News
0